This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.Here is a sample of this item:DARA BioSciences Presented Results of Its Phase 2 Study for KRN5500 at the "12th International Conference on the Mechanisms and Treatment of Neuropathic Pain" 2009-11-23 15:42 ET - News Release RALEIGH, N.C., Nov. 23, 2009 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA), a biopharmaceutical development company, presented clinical data results for KRN5500, its lead compound for Neuropathic Pain, which achieved its primary endpoint of pain reduction and demonstrated superior performance vs. Placebo (p=0.03). These study results were presented at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain, held November 19-21, 2009 in San Francisco.
Sharon M. Weinstein, MD, a leading investigator in the study, presented a poster entitled "KRN5500 Demonstrates Significant Reduction in Neuropathic Pain Intensity in Patients with Cancer." The presentation provided an overview of the results from the recently completed multicenter, placebo-controlled, blinded, randomized, parallel group study designed to evaluate the safety and efficacy of KRN5500 in patients with neuropathic pain and advanced cancer. In this study KRN5500 demonstrated clinical proof of concept by meeting the primary efficacy endpoint of pain reduction.
The remainder is available to Stockwatch subscribers.
If you would like to give the Stockwatch system a try,
click here for a free 30 day trial subscription. |
Top
Print this Page